NCT06291064RecruitingPhase 2
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (estimated)
- First submitted
- 19 Feb 2024
- Start date
- 18 Mar 2025
- Primary completion date
- Jun 2029
- Lead sponsor
- University of Chicago
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT06291064
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 85
- From 18 Mar 2025 to the primary completion date, Jun 2029
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious, uncontrolled, concurrent infection(s).
- Participation in any investigational drug study within 4 weeks preceding the start of study treatment
Other illness
- Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS)
- Other serious uncontrolled medical conditions that the treating investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.
Other
- Pregnant or lactating women.
- Patients with distant metastasis (brain and/or visceral metastasis)
Who the study is looking for
- Women ages of 18 to 70 years old
- Women who are able and willing to read understand and sign an informed consent document
- Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm)
- Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are low estrogen reception (ER) expression (\< 20%), progesterone receptor (PR) negative and human epidermal growth factor 2 (HER2) negative are eligible.
- Clinical stages IIA -IIIC (AJCC 2009)
- Chemotherapy-naïve patients (for this cancer)
- Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Non-pregnant and not nursing.
- Granulocyte greater than or equal to 1,500/microliter
- Platelet count greater than or equal to 100,000/microliter
- Absolute neutrophil count (ANC) greater than or equal to l500/microliter
- Hemoglobin greater than or equal to 10g/deciliter
- Bilirubin less than or equal 1.5 x upper limit of normal
- aspartate aminotransferase (ALT or SGOT) and alanine transaminase (AST or SGPT) less than 2.5 x upper limit of normal
- 7\. Creatinine within institutional normal limits or glomerular filtration rate greater than or equal to 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation 10. Baseline left ventricular ejection fraction of greater than or equal to 55%
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ibadan Hospital Coordinator of this site? Confirm its status | Ibadan | Nigeria | Recruiting |
| Lagos State University Teaching Hospital Coordinator of this site? Confirm its status | Ikeja | Nigeria | Recruiting |
| Obafemi Awolowo University Teaching Hospitals Complex Coordinator of this site? Confirm its status | Ile-Ife | Nigeria | Recruiting |
| Lagos University Teaching Hospital Coordinator of this site? Confirm its status | Yaba | Nigeria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.